Trial Profile
A phase II proof of concept study to evalute the efficacy and safety of deep subcutaneous lanreotide Autogel 120 mg / 28 days on symptoms and healing of the esophageal and gastric mucosa in patients with gastro esophageal reflux resitant to standard therapy (combination of proton pump inhibitors and H2 antagonists)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2014
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary)
- Indications Gastro-oesophageal reflux
- Focus Proof of concept; Therapeutic Use
- 12 Sep 2014 New trial record